WP
NVCR icon

Woodline Partners’s NovoCure NVCR Stock Holding History

Woodline Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-391,459
Closed -$5.84M – 602
2023
Q4 		$5.84M Buy
+391,459
New +$5.24M 0.06% 297
2022
Q3 		– Sell
-73,925
Closed -$5.14M – 803
2022
Q2 		$5.14M Buy
+73,925
New +$5.57M 0.08% 257
2022
Q1 		– Sell
-10,343
Closed -$777K – 794
2021
Q4 		$777K Buy
+10,343
New +$1.04M 0.01% 526

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners's NVCR Position: Q1 2024 in Review

Woodline Partners sold out of NovoCure (NVCR) in Q1 2024, closing a stake of 391,459 shares — an estimated $5.84M sold.

Woodline Partners first reported a position in NVCR in Q4 2021 and held it in 3 quarters. The position peaked at $5.84M in Q4 2023. 237 funds tracked by Wall St. Rank hold NVCR as of Q1 2024.

  • Woodline Partners reported no remaining NovoCure position as of Q1 2024 after selling out during the quarter.
  • Woodline Partners sold 391,459 NovoCure shares in Q1 2024, an estimated $5.84M.
  • Woodline Partners first reported a position in NovoCure in Q4 2021 and held it in 3 quarters.
  • Woodline Partners's NovoCure position peaked at $5.84M in Q4 2023.
  • 237 funds tracked by Wall St. Rank held NovoCure as of Q1 2024.

Based on Woodline Partners's 13F filing for Q1 2024, filed 15 May 2024.